Your fact-checks will appear here
Processing Network
Large surveillance studies and safety summaries show different rare long‑term risks for the Janssen (J&J) adenovirus vaccine versus mRNA vaccines: J&J has been associated with rare thrombosis with thr...
Large safety reviews and surveillance systems report that most consequences of Pfizer and Moderna mRNA COVID-19 vaccines are short‑lived (local pain, fatigue, fever) but rare serious events have been ...
Clinical trials and pooled analyses consistently identify gastrointestinal effects — especially nausea, diarrhea, vomiting and constipation — as the most common adverse reactions to tirzepatide, while...
Vaccine adverse event reporting systems such as VAERS (U.S.), the UK Yellow Card, and EudraVigilance collect reports of events that happen after vaccination but do not by themselves confirm that a vac...
Post-marketing pharmacovigilance analyses of tirzepatide identify disproportionate reporting for pancreato-biliary events (including pancreatitis), thyroid-related events, and eye-related events acros...
Real‑world pharmacovigilance and observational studies consistently identify gastrointestinal events—nausea, vomiting, diarrhea, constipation and dyspepsia—as the most common adverse events (AEs) with...
Pharmacovigilance and recent reviews report psychiatric adverse events (AEs) — including depressive symptoms and suicidal thoughts — in users of GLP‑1 receptor agonists and tirzepatide, but reports ar...
Available reporting shows no clear pharmacokinetic CNS‑drug interactions unique to tirzepatide but does document psychiatric adverse events in real‑world surveillance and case reports that clinicians ...
Clinical trials and meta-analyses find that oral 5‑alpha‑reductase inhibitors (5‑ARIs) — finasteride and dutasteride — increase the risk of sexual adverse events (erectile dysfunction, decreased libid...
Tirzepatide commonly causes gastrointestinal side effects—nausea, vomiting, diarrhea—more often than placebo and leads to higher discontinuation at higher doses (OR for AEs 1.34; discontinuation OR 2....
Reports through 2024 link Janssen’s Ad26.COV2.S (J&J/Janssen) vaccine to rare immune-mediated neurological events, most consistently Guillain–Barré syndrome (GBS); U.S. safety reviews found an increas...
Large, high-quality surveillance and guideline reviews conclude COVID‑19 vaccines have rare but identifiable serious risks in specific groups — most notably myocarditis/pericarditis in younger males a...
The three documents provided contain no substantive data on neurological adverse events after COVID vaccination or after COVID infection for 2021–2024, so . Each source addresses unrelated technical t...